Deutsche Bank Remains Positive on Arrowhead Research Corp. Despite Weakness

In a report published Tuesday, Deutsche Bank analyst Alethia Young reiterated a Buy rating and $45.00 price target on

. In the report, Deutsche Bank noted, “There is weakness in overall biotech sentiment that has put pressure on ARWR shares. We remain positive on risk reward into their data in 3q. Arrowhead announced that they have started dosing in Hong Kong. Timelines remain on track for 3q14 top line data in their single dose study with HBV infected patients. Arrowhead remains the leader on timelines. We project arrowhead is about a year ahead since they completed their healthy study in late 2013. „We think the ISIS announcement provides corroborating evidence that antisense/ RNA interference is a reasonable way to target HBV (in particular surface antigen). We see this as an attractive program for ISIS. „We think the HBV market is large enough to have many developers in the space. Dosing frequency, efficacy, and tolerability will be important factors in determining long-term profile.” Arrowhead Research Corp. closed on Monday at $17.37.